A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana,\u00a0on March 17, 2024.<\/p>\n
Scott Olson | Getty Images<\/p>\n
Eli Lilly<\/a> on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.<\/p>\n Shares of the company rose 5% in premarket trading Thursday.<\/p>\n The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from a previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, up from its previous outlook of $21.75 to $23 a share.<\/p>\n Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount.\u00a0<\/p>\n Zepbound, which entered the market roughly two years ago, posted $3.57 billion in revenue for the third quarter. <\/strong>That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.<\/p>\n Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:\u00a0<\/p>\n The results come as Eli Lilly<\/a> works to maintain its edge over chief rival Novo Nordisk<\/a> in the booming market for a class of obesity and diabetes drugs called GLP-1s.<\/p>\n This story is developing. Please check back for updates.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana,\u00a0on March…\n","protected":false},"author":3,"featured_media":342987,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[9165,150,9167,64,81,37520,9166,7069,152,67,132,68],"class_list":{"0":"post-342986","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-biotech-and-pharmaceuticals","9":"tag-biotechnology","10":"tag-breaking-news-business","11":"tag-business","12":"tag-business-news","13":"tag-eli-lilly-and-co","14":"tag-health-care-industry","15":"tag-novo-nordisk-a-s","16":"tag-pharmaceuticals","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115462841691262045","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/342986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=342986"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/342986\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/342987"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=342986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=342986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=342986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n